Abstract
BackgroundThe aggressiveness of melanoma tumors is likely to rely on their well-recognized heterogeneity and plasticity. Melanoma comprises multi-subpopulations of cancer cells some of which may possess stem cell-like properties. Although useful, the sphere-formation assay to identify stem cell-like or tumor initiating cell subpopulations in melanoma has been challenged, and it is unclear if this model can predict a functional phenotype associated with aggressive tumor cells.Methodology/Principal FindingsWe analyzed the molecular and functional phenotypes of melanoma spheroids formed in neural crest cell medium. Whether from metastatic or advanced primary tumors, spheroid cells expressed melanoma-associated markers. They displayed higher capacity to differentiate along mesenchymal lineages and enhanced expression of SOX2, NANOG, KLF4, and/or OCT4 transcription factors, but not enhanced self-renewal or tumorigenicity when compared to their adherent counterparts. Gene expression profiling attributed a neural crest cell signature to these spheroids and indicated that a migratory/invasive and immune-function modulating program could be associated with these cells. In vitro assays confirmed that spheroids display enhanced migratory/invasive capacities. In immune activation assays, spheroid cells elicited a poorer allogenic response from immune cells and inhibited mitogen-dependent T cells activation and proliferation more efficiently than their adherent counterparts. Our findings reveal a novel immune-modulator function of melanoma spheroids and suggest specific roles for spheroids in invasion and in evasion of antitumor immunity.Conclusion/SignificanceThe association of a more plastic, invasive and evasive, thus a more aggressive tumor phenotype with melanoma spheroids reveals a previously unrecognized aspect of tumor cells expanded as spheroid cultures. While of limited efficiency for melanoma initiating cell identification, our melanoma spheroid model predicted aggressive phenotype and suggested that aggressiveness and heterogeneity of melanoma tumors can be supported by subpopulations other than cancer stem cells. Therefore, it could be constructive to investigate melanoma aggressiveness, relevant to patients and clinical transferability.
Highlights
Melanoma represents one of the most aggressive malignancies with a high tendency to invade secondary sites
Whether from a lymph node metastasis (SLM8) or from a primary stage IV-cutaneous lesion (Mela1), melanoma cells when seeded at a clonal density in neural crest cells medium form small floating spheroid structures (15–30 cells) within 2 days of culture that grow to approximately 200 cells each within 2 weeks (Fig. 1A)
25.464.7% and 31.561.0% of SLM8 and Mela1 spheroids and 11.963.4% and 17.462.3 of their adherent counterparts, respectively, presented alkaline phosphatase activity (Fig. 2B right panel). These results show higher capacity of spheroid cells to differentiate along mesenchymal lineages and suggest that melanoma spheroids grown under neural crest cell conditions are enriched with multipotent cells when compared to their adherent counterparts
Summary
Melanoma represents one of the most aggressive malignancies with a high tendency to invade secondary sites. Melanoma presents a variety of phenotypic and behavioral features. Melanoma tissues have various morphologies and immunohistochemical staining of melanoma lesions for specific markers often leads to heterogeneous results [1,2,3]. One explanation for the therapeutic failures might reside in the selective targeting of melanoma cells due to their heterogeneity. The aggressiveness of melanoma tumors is likely to rely on their well-recognized heterogeneity and plasticity. Melanoma comprises multi-subpopulations of cancer cells some of which may possess stem cell-like properties. The sphere-formation assay to identify stem cell-like or tumor initiating cell subpopulations in melanoma has been challenged, and it is unclear if this model can predict a functional phenotype associated with aggressive tumor cells
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have